Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Rajesh Kharbanda , Tessel Vossenberg Added: 1 year ago
In this exclusive interview, Dr Tessel Vossenberg (Medical Center Leeuwarden, Leeuwarden, NL) speaks with Prof Rajesh Kharbanda (Oxford University Hospitals NHS Foundation Trust, UK),Principal Investigator of the BHF PROTECT TAVI trial.This highly anticipated trial aims to provide groundbreaking insights into the field of Cerebral Embolic Protection (CEP) in TAVI. In this interview, Dr… View more
Author(s): Nicolas M Van Mieghem , Danny Dvir , , et al Added: 1 year ago
This Breakout, held at Transcatheter Interventions Online 2024, discovers the concept of sensor-guided TAVI interventions using a dedicated LV-pacing guidewire designed to deliver efficient, predictable outcomes. Explore the potential benefits of continuous pressure gradient measurements, understand their impact on TAVI workflow enhancements and how continuous pressure gradient monitoring can… View more
Author(s): Dirk-Jan van Ginkel Added: 7 months ago
ESC Congress 2024 — No benefit of continuing oral anticoagulation during TAVI procedure.Investigator, Dr Dirk-Jan van Ginkel (St Antonius Hospital, NL) joins us to discuss the result of the POPular PAUSE TAVI trial (NCT04437303; St Antonius Hospital). Presented for the first time at ESC 2024, this multicenter, randomized, open-label clinical trial compared the safety and efficacy of continuous… View more
Author(s): David Hildick-Smith , Giuseppe Tarantini , Lars Søndergaard , et al Added: 2 years ago
This symposium, part of Transcatheter Interventions Online 2023, and chaired by ProfDavid Hildick-Smith (Brighton & Sussex University Hospitals NHS Trust,Brighton, UK), featured a panel discussion on the latest data on durability and clinical outcomes, an analysis of how TAVI is changing and possible future options for patients with aortic valve disease. The symposium also featured a minimalistic… View more
Author(s): Hans-Josef Feistritzer Added: 11 months ago
EuroPCR 24 - In this succinct interview, we are joined by Dr Hans-Josef Feistritzer (University of Leipzig, DE) to discuss the findings of the SOLVE-TAVI Trial.In recent years, trials such as CHOICE, REPRISE III, the SCOPE trial, PORTICO IDE and the SMART trial have privided increasing evidence for direct TACI valve comparisons as device designs improve. TAVI is increasingly performed using local… View more
Author(s): Roxana Mehran , Martin Swaans , Haim Danenberg , et al Added: 1 year ago
In this video series, first presented at the ESC Congress 2023 held in Amsterdam, Prof Roxana Mehran, Dr Antoinette Neylon, Dr Martin Swaans, Prof Raphael Rosenhek and Prof Haim Danenberg discuss the Expand II TAVR pivotal trial design and the rational for investigating the treatment of moderate aortic stenosis patients with Evolut™ TAVI, provide practical Echo imaging recommendations to improve… View more
Author(s): Jacob Thomsen Lønborg Added: 7 months ago
ESC Congress 2024 — FFR-guided PCI improves outcomes in TAVI patients with coronary artery disease.Principal investigator, Prof Jacob Thomsen Lønborg (Rigshospitalet, DK) joins us to discuss the NOTION-3 trial (NCT03058627). A multinational, open-label, investigator-initiated trial evaluated the efficacy of FFR-guided PCI versus medical therapy in managing coronary artery disease (CAD) among… View more
Author(s): Vijay Kunadian Added: 7 months ago
This video series includes a symposium first presented at ESC 2024 held in London, where Prof Roxana Mehran, Prof Vijay Kunadian, Dr Didier Tchetche, Dr Julia Grapsa and Dr Joanna J Wykrzykowska discuss transforming TAVI practice. The discussion covers topics such as the SMART trial, a comparison of the most commonly used TAVI valves and strategies to address disparities in diagnosing aortic… View more
Author(s): Added: 5 days ago
EHRA 2025 - Long-term insights from pacemaker implantation after transcatheter aortic valve implantation (TAVI) show patients receiving pacemaker therapy within 30 days after TAVI had a significantly worse prognosis compared to patients with no pacemaker therapy in regards to all-cause death and CV death at one, five and ten year follow-ups.Prof Patrick Badertscher (University Hospital Basel,… View more